Moderna Inc. said a modified version of its Covid-19 vaccine induced potent immune responses against fast-spreading Omicron subvariants among volunteers in a new study.
One month after receiving the company’s tweaked shot, study subjects’ neutralizing antibodies against Omicron subvariants BA.4 and BA.5 increased significantly, regardless of whether they were previously infected, Moderna said Wednesday.
